Sabal Trust CO Invests $490,000 in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE)

Sabal Trust CO acquired a new position in shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 7,461 shares of the company’s stock, valued at approximately $490,000.

Other hedge funds have also made changes to their positions in the company. US Bancorp DE boosted its holdings in shares of iShares U.S. Pharmaceuticals ETF by 137.0% during the third quarter. US Bancorp DE now owns 384 shares of the company’s stock worth $27,000 after purchasing an additional 222 shares during the last quarter. Assetmark Inc. boosted its holdings in shares of iShares U.S. Pharmaceuticals ETF by 100.0% during the third quarter. Assetmark Inc. now owns 432 shares of the company’s stock worth $31,000 after purchasing an additional 216 shares during the last quarter. Union Bancaire Privee UBP SA acquired a new stake in shares of iShares U.S. Pharmaceuticals ETF during the fourth quarter worth $42,000. Allworth Financial LP boosted its holdings in shares of iShares U.S. Pharmaceuticals ETF by 9.4% during the third quarter. Allworth Financial LP now owns 1,853 shares of the company’s stock worth $131,000 after purchasing an additional 159 shares during the last quarter. Finally, EP Wealth Advisors LLC acquired a new stake in shares of iShares U.S. Pharmaceuticals ETF during the third quarter worth $157,000.

iShares U.S. Pharmaceuticals ETF Stock Down 0.4 %

IHE stock opened at $72.54 on Thursday. iShares U.S. Pharmaceuticals ETF has a 52-week low of $62.68 and a 52-week high of $73.11. The stock’s fifty day simple moving average is $68.16 and its 200-day simple moving average is $69.35. The stock has a market capitalization of $732.65 million, a price-to-earnings ratio of 6.49 and a beta of 0.58.

iShares U.S. Pharmaceuticals ETF Profile

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.